Nikhith Rao

Nikhith Rao

Auto-generated profile, based on publicly available information

Nikhith Rao

University of Missouri-Kansas City School of Medicine, Kansas City, MO

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2026 in Cornea
Verified
Journal Article
Closed access
DMDavid M. Morcos
David M. Morcos
BCBlaze A. Carbonell
Blaze A. Carbonell
NRNikhith Rao
Nikhith Rao
MKMelisa Karslioglu
Melisa Karslioglu
JFJosé A. P. M. Filho
José A. P. M. Filho
OLOlivia L. Lee
Olivia L. Lee
Purpose: To describe the risk factors, clinical course, and characteristics of 5 cases of acute calcific band keratopathy (BK) after the use of recombinant human nerve growth factor for neurotrophic keratitis. Methods: A single-center retrospective chart review of 43 eyes of 43 patients previously diagnosed with neurotrophic keratitis from April 2021 to October 2023 was conducted. All patients had previously completed at least one 8-week course of topical cenegermin 0.002%. Five of the 43 cenegermin-treated eyes that developed BK are included in this series. Results: The incidence of BK was 11.6%. The median time from treatment initiation to BK was 8 weeks. A corneal biopsy confirmed the presence of calcification in 2 cases. All 5 patients had persistent calcium deposits after discontinuing treatment. Prolonged epithelial defect healing time while on treatment was observed in patients who developed BK. Conclusions: BK was observed after cenegermin use. Herein, we report a series of 5 cases, which occurred at the same institution. Ethylenediaminetetraacetic acid chelation therapy had variable results, with 4 out of 5 patients requiring repeated surgical intervention because of multiple recurrences of BK.